Jonathan Biller named chief legal officer at Vertex

8 September 2022

US biotech Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that Jonathan Biller has been appointed chief legal officer, effective September 19, 2022.

Mr Biller will report directly to Vertex’ chief executive and president, Dr Reshma Kewalramani, and join the company’s executive committee. In this role, Mr Biller will oversee all of Vertex’s global legal and compliance functions.

“Jonathan is an outstanding addition to Vertex with his deep legal, industry and business experience, and I am delighted to welcome him to the company,” said Dr Kewalramani, adding: “Jonathan will lead an extraordinarily talented legal and compliance team and support our continued growth as we expand our leadership in cystic fibrosis, advance the pipeline across multiple diseases and modalities, and invest in the next wave of innovation.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK